Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/3/2024 | $62.00 | Mkt Outperform | JMP Securities |
6/13/2024 | $53.00 | Neutral | JP Morgan |
2/13/2024 | $72.00 | Overweight | Stephens |
1/22/2024 | $75.00 | Buy | UBS |
1/3/2024 | Outperform | William Blair | |
12/15/2023 | $62.00 → $70.00 | Buy | Needham |
10/20/2023 | $75.00 | Buy | ROTH MKM |
6/26/2023 | $70.00 | Buy | Needham |
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
4 - Enovis CORP (0001420800) (Issuer)
Continued commercial momentum with third-quarter sales growth of 21% on a reported basis and strong adjusted EBITDA margin expansionReconstructive sales grew 57% Y/Y on a reported basis and 9% on a Comparable basisReported third-quarter net loss from continuing operations of $0.61 per share, adjusted net income per diluted share of $0.73, up +30% Y/Y Wilmington, DE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended September 27, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:3
Wilmington, DE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715
Continued strong momentum with second-quarter sales growth of 23% on a reported basis and strong adjusted margin expansionReported second-quarter net loss from continuing operations of $0.34 per share with adjusted net income per diluted share of $0.62Advanced strategic goals with solid first half of 2024, slightly ahead of expectations, and set up to accelerate in the second half of the year Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss
JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00
JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00
Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
SC 13G/A - Enovis CORP (0001420800) (Subject)
Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025. Visentin is a successful MedTech executive who comes to Enovis with more than 20 years of healthcare experience. Most recently, he was the Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit for BD, where he managed more than 700 employees across 50 countries and gained market share in a very competitive market. Prior to BD, Visentin served as Vice President and General Manager
NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index
Wilmington, DE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 43nd Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 13th, 2025, at 9:45 a.m. PST (12:45 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company's website (www.enovis.com) at Events and Presentations. ABOUT ENOVIS Enovis Corporation (NYSE:ENOV) is an innovation-driven medical technology growth company dedicated to developing
8-K - Enovis CORP (0001420800) (Filer)
SCHEDULE 13G - Enovis CORP (0001420800) (Subject)
10-Q - Enovis CORP (0001420800) (Filer)
NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index
WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and